iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
iTeos Therapeutics, Inc. (ITOS) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City on November 28, 2023. The company focuses on immune-oncology therapeutics for patients.
11/21/2023 - 07:00 AM
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET.
A live webcast of the event will be available on the Investor section of the Company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT:CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos Therapeutics routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos Therapeutics.
For further information, please contact:
Investor Contact:
Carl Mauch
Media Contact:
media@iteostherapeutics.com
What is the upcoming event iTeos Therapeutics, Inc. (ITOS) will participate in?
iTeos Therapeutics, Inc. (ITOS) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City on November 28, 2023.
What is the focus of iTeos Therapeutics, Inc. (ITOS)?
iTeos Therapeutics, Inc. (ITOS) focuses on the discovery and development of a new generation of immune-oncology therapeutics for patients.
Where can I watch the live webcast of the event?
A live webcast of the event will be available on the Investor section of the Company’s website at https://www.iteostherapeutics.com.
How long will the archived replay of the event be available?
An archived replay will be available for approximately 30 days following the presentation.
ITOS Rankings
#4779 Ranked by Stock Gains
ITOS Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
About ITOS
starting operations in 2012, iteos therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iteos is developing eos200271, a clinical-stage potent and selective ido1 inhibitor with exceptional brain penetration. the company is also advancing eos100850, an insurmountable and non-brain penetrant adenosine a2a receptor antagonist, into a phase 1 trial in the second half of 2018; and a human adcc-enabling anti-tigit antibody (eos884448), representing an additional, third clinical entry in 2019. based in gosselies, belgium, iteos therapeutics was founded and supported in part by investments from the ludwig institute cancer research (licr), the walloon region of belgium and the european fund for economic and regional development (feder). for more information, please visit www.iteostherapeutics.com.
